The Pipeline for New MASLD & MASH Treatments is Promising, says Naim Alkhouri, MD
Following the landmark FDA approval of resmetirom for MASH with fibrosis, hepatologist and researcher Alkhouri describes more mid- and late-stage candidates.
Dermavant: FDA Accepts sNDA for Tapinarof Cream 1% for Treatment of Adults, Children with Atopic Dermatitis
The FDA PDUFA date for taparinof cream 1% will be during the 4th quarter, Dermavant said, with approval based on ADORING phase 3 clinical trial data.
A MASLD Mantra to Practice By: Screen, Stage, Treat
Hepatologist Naim Alkhouri, MD, offered 3 take-home thoughts for primary care colleagues to help increase early detection of MASLD.
Merck's 21-Valent Pneumococcal Vaccine Delivers More Positive Phase 3 Data in Advance of 6-17-2024 PDUFA Date
In STRIDE 10, V116 was superior to PPSV23 in adults aged ≥50 years and naive to pneumococcal vaccine for 8 of 9 serotypes unique to Merck's investigational shot.
The FDA Approval of Resmetirom for MASH Changes Everything—for Patients and their Physicians
Naim Alkhouri, MD, a transplant hepatologist and a resmetirom investigator, talks here about the life-changing impact the drug will have for all touched by MASH.
Early Detection of MASLD in Primary Care: The Essentials with Naim Alkhouri, MD
Primary care is where early detection and treatment of liver disease should begin and as Dr Alkhouri highlights here, all the right tools are already at hand.
American Liver Foundation Announces First Federally-Funded Research on MASLD
The national study on the true prevalence of metabolic dysfunction-associated liver disease is essential to screening, prevention, and treatment efforts, says AFL CEO Stiehl.
Adults with Obesity Who Receive Semaglutide as First Weight Loss Medication Lose More Weight
Adults receiving semaglutide for the first time achieved weight loss of 14.3% at 12 months vs 10.6% among those who had previously taken a different antiobesity drug.
Shingrix Effective Against Shingles for up to 11 Years Post-Vaccination: Daily Dose
Your daily dose of the clinical news you may have missed.
FDA Approves First New Antibiotic in Decades for Uncomplicated UTI
Pivmecillinam is an aminopenicillin, a class of beta-lactam antibiotics with a mechanism of action that may help reduce rising levels of antibiotic resistance.
Food vs Medicine for IBS: Dietary Measures First, New Study Suggests
More participants consuming either of 2 common IBS dietary regimens experienced significant and sustained symptom relief vs those given pharmacotherapy.
Poor Cardiovascular Health at Midlife Linked to Cognitive Decline in Black Women
Poor cardiovascular health at midlife was associated with a decline in the mental processing speed of Black women, but not White women, according to a new study.
Elevated Lp(a) Level Raises ASCVD Risk Regardless of Age, Sex, Race/Ethnicity: Daily Dose
The Rate of Undetected MASLD in the US is a Sobering Statistic, says Expert Hepatologist Naim Alkhouri, MD
Alkhouri, a veteran investigator in the field of hepatic disease, including MASLD and MASH, stresses the need for early detection of MASLD when simple intervention can be effective.
The Price of the US Health Care Affordability Crisis: High Anxiety, Skipped Care, Failing Health
To cover a medical bill, more than half of those surveyed would downsize a home, 75% would take on a second job; more than 1/3 had already skipped care due to costs.
New Data Suggest Atrial Fibrillation May be More Common in Younger Adults than Previously Thought
Patients with AF aged younger than 65 years have substantial comorbidity burden that may impact their future risk of mortality, reported researchers.
Breathlessness Related to Medical Conditions in Middle-Aged Adults: Daily Dose
Treatment by Female Physicians Linked to Lower Mortality, Hospital Readmissions
Treatment by female physicians resulted in better 30-day outcomes for male and female patients, but the benefit was significantly greater for the women.
Maternal Vascular Indices, Biomarkers at 36 Week's Gestation Predict Preeclampsia, New Study Concludes
Increased arterial stiffness and elevated central BP are among factors researchers found to have strong discriminatory value for PE at term and postpartum.
Study: COVID-19 Booster Shots Elicit Longer Immunity than Primary Series Alone
Researchers found that the COVID-19 booster dose elicited a 71%-84% increase in the median anti-spike half-life over that of the primary series.
